Mainz Biomed Provides Product Development Update on PancAlert
May 05, 2022 03:01 ET
|
Mainz BioMed NV
Novel Screening Test for Pancreatic Cancer Funded by the German GovernmentAchieved Key Project Milestones; Next Phase of Development Launched BERKELEY, Calif. and MAINZ, Germany, May 05, 2022 ...
Mainz Biomed Appoints Darin Leigh as Chief Commercial Officer
April 26, 2022 03:01 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, April 26, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed Announces First Quarter 2022 Results
April 12, 2022 03:01 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, April 12, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed Completes Successful Pre-Submission Process with the U.S FDA for ColoAlert’s Pivotal Clinical Trial
March 31, 2022 03:01 ET
|
Mainz BioMed NV
Multi-Center Study on Track to Commence in Late 2022Initiated Reimbursement Process with The Centers for Medicare and Medicaid Services BERKELEY, Calif. and MAINZ, Germany, March 31, 2022 (GLOBE...
Mainz Biomed to Ring Nasdaq Stock Market Closing Bell
March 21, 2022 03:01 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, March 21, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed Appoints Key Clinical Trial Partners for ColoFuture Study
March 17, 2022 03:01 ET
|
Mainz BioMed NV
Cutting Edge IVD Developer Sentinel Chosen to Provide Automated FIT Analysis SystemLeading Clinical Research Organization Alcedis Selected to Manage the Study - ColoFuture on track to complete...
Mainz Biomed Announces Year End 2021 Results
March 09, 2022 03:01 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, March 09, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed and Partners Join International Awareness Campaign for Colorectal Cancer Awareness Month
March 02, 2022 03:01 ET
|
Mainz BioMed NV
Mainz Biomed joins a collective of physicians, healthcare professionals, laboratories and healthcare organizations as part of the international Colorectal Cancer Awareness Month initiative ...
Mainz Biomed Provides U.S. Regulatory Review Update for ColoAlert
February 23, 2022 03:01 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed Expands ColoAlert Commercialization with German Laboratory MVZ Dr. Stein + Kollegen, Mönchengladbach
February 14, 2022 03:01 ET
|
Mainz BioMed NV
Laboratory Stein is part of the Limbach Group, which is the largest network of laboratories in Germany and one of the largest networks of laboratories in EuropeLaboratory MVZ Dr. Stein + Kollegen...